Soni Medicare

Who are the top shareholders of the Soni Medicare?

The top shareholder of Soni Medicare is B R Soni, holding 39.1% of the shares, with Sahil Chabra as the highest public shareholder at 4.69%. Individual investors collectively own 25.15% of the shares, and there are no pledged promoter holdings or institutional investors.

The top shareholders of Soni Medicare include the promoters, with B R Soni holding the highest stake at 39.1%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares. The highest public shareholder is Sahil Chabra, who owns 4.69%. Additionally, individual investors collectively hold 25.15% of the shares.

how big is Soni Medicare?

As of Jun 06, Soni Medicare Ltd has a market capitalization of 23.00 Cr, classifying it as a Micro Cap company, with net sales of 29.83 Cr and a net profit of -0.18 Cr over the latest four quarters. The company has shareholder's funds of 1.62 Cr and total assets of 19.66 Cr as of Mar'24.

Market Cap: As of Jun 06, Soni Medicare Ltd has a market capitalization of 23.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Soni Medicare reported net sales of 29.83 Cr and a net profit of -0.18 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is based on Standalone data for the reporting period ending Mar'24. The company has shareholder's funds of 1.62 Cr and total assets amounting to 19.66 Cr.

What does Soni Medicare do?

Soni Medicare Ltd is a micro-cap company in the hospital industry, incorporated in 1988, with recent quarterly net sales of 7 Cr and a market cap of Rs 23 Cr. The company reported a net profit of 0 Cr for March 2025 and has a high debt-equity ratio of 6.60.

Overview: <BR>Soni Medicare Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History: <BR>Soni Medicare Limited was incorporated in 1988 as 'Soni Hospital Private Limited'. The company changed its name to Soni Medicare Private Limited in 1995 and later became a Public Limited Company. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 7 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 23 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 6.60 <BR>Return on Equity: -13.95% <BR>Price to Book: 18.20<BR><BR>Contact Details: <BR>Address: 38 Kanota Bagh, Jawahar Lal Nehru Marg Jaipur Rajasthan : 302004 <BR>Tel: 91-141-5163700 <BR>Email: jpsassociates@hotmail.com <BR>Website: http://www.sonihospitals.com

Who are in the management team of Soni Medicare?

As of March 2022, the management team of Soni Medicare includes Anju Soni (Director), Bimal Roy Soni (Chairman & Managing Director), Mahavir Prasad Yadav, Mamta Sharma, and Naveen Sanghi (all Independent Directors), along with Juhi Gurnani (Company Secretary & Compliance Officer). Each member contributes to the company's governance and management.

As of March 2022, the management team of Soni Medicare includes the following members:<BR><BR>1. Anju Soni - Director<BR>2. Bimal Roy Soni - Chairman & Managing Director<BR>3. Mahavir Prasad Yadav - Independent Director<BR>4. Mamta Sharma - Independent Director<BR>5. Naveen Sanghi - Independent Director<BR>6. Juhi Gurnani - Company Secretary & Compliance Officer<BR><BR>Each member plays a significant role in the governance and management of the company.

Has Soni Medicare declared dividend?

No Dividend History Available

Who are the peers of the Soni Medicare?

Soni Medicare's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, and Broach. Soni Medicare has a 1-year return of 124.83%, outperforming its peers, while it has below-average growth and capital structure compared to others.

Peers: Soni Medicare's peers include Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., and Broach.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., and Rainbow Child., while Average management risk is found at Fortis Health., Aster DM Health., Broach, and Docmode Health. Good growth is seen in Max Healthcare, Apollo Hospitals, Narayana Hrudaya, and Fortis Health., while Below Average growth is noted at Aster DM Health., Krishna Institu., Rainbow Child., and Soni Medicare. Excellent capital structure is present in Max Healthcare, Global Health, and Krishna Institu., while Average capital structure is found at Apollo Hospitals, Fortis Health., and Broach, and Below Average capital structure is noted at Aster DM Health., Soni Medicare, and Docmode Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.47%, while the lowest is Broach, which has no available data. Soni Medicare's own 1-year return is 124.83%, which is significantly higher than all peers. Additionally, Aster DM Health. and Broach have negative six-month returns.

What is the technical trend for Soni Medicare?

As of March 17, 2025, Soni Medicare's technical trend is bullish, supported by positive MACD and KST indicators, despite mixed signals from Bollinger Bands and Dow Theory.

As of 17 March 2025, the technical trend for Soni Medicare has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. The KST is also bullish on both time frames, reinforcing the bullish stance. While the Bollinger Bands indicate a mildly bullish position on both weekly and monthly charts, the daily moving averages are only mildly bullish. The Dow Theory presents a mixed view, being mildly bearish on the weekly chart but bullish on the monthly chart. Overall, the current technical stance is bullish, with strong support from MACD and KST indicators, despite some mixed signals from other indicators.

When is the next results date for Soni Medicare?

The next results date for Soni Medicare is 14 November 2025.

The next results date for Soni Medicare is scheduled for 14 November 2025.

Are Soni Medicare latest results good or bad?

Soni Medicare's latest results show a mixed performance; while profitability has improved with a Profit After Tax of Rs 0.06 crore compared to a loss last year, the company faces challenges with declining net profit and a low Debtors Turnover Ratio, leading to a 'Sell' rating from MarketsMOJO.

Soni Medicare's latest results present a mixed picture. On one hand, the company has shown a notable improvement in profitability, reporting a Profit After Tax (PAT) of Rs 0.06 crore for the latest six-month period, a significant turnaround from a loss of Rs 1.42 crore in the previous year. This indicates that Soni Medicare has managed to surpass its PAT from the last year within just half a year, which is a positive development.<BR><BR>However, the overall financial performance for the quarter ending June 2025 has been flat, with a decline in its performance score from 3 to 2 over the past three months. Additionally, while net sales have grown by 5.97% compared to the previous quarter, the standalone net profit has seen a drastic decline of 182.86%. This suggests that while sales are increasing, the company is struggling to translate that into profit effectively.<BR><BR>Moreover, the Debtors Turnover Ratio has reached its lowest point in the last five half-yearly periods at 3.41 times, indicating challenges in managing debts and potentially impacting cash flow and operational efficiency. The stock has also been rated as a 'Sell' by MarketsMOJO, reflecting a cautious sentiment regarding the company's current performance.<BR><BR>In summary, while there are some positive signs in terms of profitability, the overall financial results indicate significant challenges that could affect the company's future performance.

Is Soni Medicare overvalued or undervalued?

As of November 17, 2025, Soni Medicare is considered risky and overvalued due to troubling financial ratios, including a PE ratio of -43.73 and an EV to EBITDA of 51.80, despite a year-to-date stock return of 210.97% that lags behind the Sensex's 8.72% return.

As of 17 November 2025, Soni Medicare's valuation grade has moved from attractive to risky, indicating a significant shift in its financial outlook. The company appears to be overvalued, particularly given its troubling ratios, including a PE ratio of -43.73, an EV to EBITDA of 51.80, and a ROE of -76.74%. These figures suggest that the company's earnings are not only negative but also that it is trading at a high multiple relative to its earnings before interest, taxes, depreciation, and amortization.<BR><BR>In comparison to its peers, Soni Medicare's valuation stands out unfavorably. For instance, Apollo Hospitals, which is rated attractive, has a PE ratio of 64.41 and an EV to EBITDA of 33.85, while Max Healthcare is categorized as very expensive with a PE of 77.22 and an EV to EBITDA of 53.09. The stark contrast in these ratios highlights Soni Medicare's riskier position within the industry. Additionally, despite a remarkable year-to-date stock return of 210.97%, the recent performance has lagged behind the Sensex, which returned 8.72% over the same period. This combination of factors reinforces the conclusion that Soni Medicare is currently overvalued.

How has been the historical performance of Soni Medicare?

Soni Medicare has experienced steady revenue growth, with net sales increasing from 14.67 Cr in Mar'19 to 29.84 Cr in Mar'25, but continues to face profitability challenges, reporting a profit after tax of -0.19 Cr in Mar'25 despite improved operational efficiency. Total liabilities and assets rose to 22.17 Cr, indicating balanced growth.

Answer:<BR>The historical performance of Soni Medicare shows a fluctuating trend in its financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Soni Medicare's net sales have increased from 14.67 Cr in Mar'19 to 29.84 Cr in Mar'25, indicating a steady growth trajectory. Other operating income has also risen, reaching 1.35 Cr in Mar'25 from negligible amounts in previous years. Total operating income has seen a similar upward trend, climbing to 31.19 Cr in Mar'25 from 14.67 Cr in Mar'19. However, total expenditure has also increased, leading to an operating profit (PBDIT) of 1.27 Cr in Mar'25, a recovery from a loss of 0.25 Cr in Mar'24. Despite this, the company has reported a profit before tax of -0.22 Cr in Mar'25, an improvement from -1.63 Cr in Mar'24, and a profit after tax of -0.19 Cr, reflecting ongoing challenges. The company's total liabilities rose to 22.17 Cr in Mar'25, up from 19.66 Cr in Mar'24, while total assets increased to 22.17 Cr as well, indicating a balance between growth in assets and liabilities. Cash flow from operating activities turned positive at 1.00 Cr in Mar'25, contrasting with previous years where it was negative, suggesting improved operational efficiency. Overall, while Soni Medicare has shown growth in sales and operating income, it continues to face challenges in achieving profitability.

Should I buy, sell or hold Soni Medicare Ltd?

Why is Soni Medicare Ltd falling/rising?

As of 02-Feb, Soni Medicare Ltd's stock price is Rs 95.70, unchanged from the previous session, but has declined 4.97% over the past week. The company faces financial challenges, including a high Debt-Equity Ratio and recent losses, indicating weak fundamentals and downward pressure on its stock.

As of 02-Feb, Soni Medicare Ltd's stock price is currently at Rs 95.70, showing no change from the previous trading session. The stock has experienced a significant decline of 4.97% over the past week and has underperformed its sector by 4.06% today. The stock opened with a loss of 4.97%, reaching an intraday low of Rs 95.70, and has not traded above this price throughout the day. <BR><BR>The company's financial health is concerning, highlighted by a high Debt-Equity Ratio of 9.62 times, indicating weak long-term fundamental strength and a low ability to service its debt, as evidenced by a Debt to EBITDA ratio of 4.34 times. Additionally, the company has reported losses, contributing to a negative Return on Equity (ROE). Recent financial results show that net sales were at their lowest for the quarter at Rs 6.51 crore, and the Debtors Turnover Ratio was also at a low of 2.86 times. <BR><BR>Despite a remarkable return of 139.25% over the past year, the company's profits have only increased by 55%, suggesting that the stock is trading at risky levels compared to its historical valuations. Furthermore, there has been a notable decline in investor participation, with delivery volume falling by 36.79% against the 5-day average. These factors collectively indicate that Soni Medicare Ltd's stock is facing downward pressure, contributing to its current price stagnation and recent declines.

Which are the latest news on Soni Medicare?